Published in Women's Health Weekly, May 31st, 1999
Recently approved for use in the United States for urinary tract infection (UTI) treatment, the benefits of fosfomycin tromethamine include easy compliance, minimal side effects, and reduced cost. More importantly, it is a new weapon against antibiotic-resistant organisms.
Gary E. Stein, PharmD, of Michigan State University, reviewed this antimicrobial in the March/April 1999 issue of the International Journal of Fertility ("Fosfomycin Tromethamine: Single-Dose Treatment of Acute Cystitis," Int J Fertil,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.